In today’s evolving landscape of type 2 diabetes management, pioglitazone (Glitaz) continues to offer unique metabolic benefits that extend beyond glycemic control.
IMPROVES INSULIN SENSITIVITY
By directly targeting insulin resistance at its core, pioglitazone (Glitaz) enhances peripheral glucose uptake and utilization – addressing a fundamental defect in T2DM.
BENEFITS IN NAFLD/NASH
Growing evidence supports pioglitazone’s role in improving liver histology, reducing hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
CARDIOVASCULAR BENEFITS: EVIDENCE
FROM THE PROACTIVE TRIAL
In the landmark PROactive trial, pioglitazone demonstrated a statistically significant reduction in key secondary cardiovascular
endpoints (all-cause mortality, myocardial infarction, stroke).